- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07897318
Mi2000 TICI - Post-market Implantation Study (TUPIS)
This Post-Market Clinical Follow-up (PMCF) investigation aims to further collect evidence on safety and performance of the Mi2000 TICI. This PMCF investigation will prospectively collect clinical data from the use of the Mi2000 TICI and related devices.
This PMCF investigation is performed on a cochlear implant system newly introduced to the market, which was previously studied in two pre-market clinical investigations. The purpose of the current clinical investigation is to collect further evidence by collecting additional clinical data on the use of the Mi2000 TICI.
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Florian Schwarze, PhD
- Telefonnummer: +4357788
- E-post: studies@medel.com
Studiesteder
-
-
-
Liège, Belgia, 4000
- Har ikke rekruttert ennå
- Centre Hospitalier Universitaire de Liège, Department ORL
-
Ta kontakt med:
- Philippe Lefebvre, Dr.med.
-
-
Belgium
-
Antwerp, Belgium, Belgia, 2650
- Har ikke rekruttert ennå
- UZA Antwerpen
-
Ta kontakt med:
- Vincent van Rompaey, Prof. Dr.
-
-
-
-
Poland
-
Nadarzyn, Poland, Polen, 05-830
- Har ikke rekruttert ennå
- The Institute of Physiology and Pathology of Hearing
-
Ta kontakt med:
- Piotr Skarzynski, Prof. Dr.
-
-
-
-
-
Würzburg, Tyskland
- Har ikke rekruttert ennå
- Universitätsklinikum Würzburg
-
Ta kontakt med:
- Kristen Rak, Prof. Dr.
-
-
Bavaria
-
München, Bavaria, Tyskland, 81377
- Rekruttering
- Klinikum der Universität München, Campus Großhadern
-
Ta kontakt med:
- Joachim Müller, Dr.med.
-
-
-
-
State of Vienna
-
Vienna, State of Vienna, Østerrike, 1090
- Har ikke rekruttert ennå
- AKH Wien
-
Ta kontakt med:
- Christoph Arnoldner, Prof. Dr.
- E-post: christoph.arnoldner@meduniwien.ac.at
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Minimum age of eighteen (18) years at time of enrolment
- Bilateral sensorineural hearing loss with no or limited benefit from a hearing aid (>70 dB HL PTA4(500, 1000, 2000, 4000Hz))
- Post-lingual onset of deafness
- No or limited benefit from hearing aids for less than 10 years and an expected benefit from cochlear implantation
- A maximum score of 50% on a word test in the language of the test center in the ear to be implanted in the best aided condition
- Fluency in the test language with excellent proficiency, as appropriate to perform speech testing
- Functional auditory nerve
- General health condition, psychological and emotional condition deemed compatible with the treatment and tests performed in this study
- Pre-operative assessment according to the local professional standards
- Candidate is highly motivated and has realistic expectations about the expected benefit of the implant and shall understand the importance of returning to the implant center for regular speech processor programming, assessment sessions and training
- Realistic expectations, as deemed appropriate by the implanting surgeon/implant board
- Signed and dated informed consent before the start of any study-specific procedure
Exclusion Criteria:
-
Lack of compliance with any inclusion criterion
-
Previously having received an implant on the location chosen for placing the cochlear implant
-
Having received a hearing implant from another manufacturer than MED-EL on the contralateral ear
-
Pre-existing condition known to necessitate MRI scans after implantation of the Mi2000 TICI
-
Women being pregnant or nursing
-
The individual is known to be intolerant of the materials used in the implant or other required accessories
-
Absence of cochlear development
-
The cause of deafness is non-functionality of the auditory nerve and/or the upper auditory pathway
-
Medical contra-indications to middle ear and/or inner ear surgery, and/or anesthesia
-
External or middle ear infections are present
-
The tympanic membrane is perforated in the ear to be implanted
-
Anatomic abnormalities are present that would prevent appropriate placement of the stimulator housing in the bone of the skull, or prevent placement of the chosen electrode array into the cochlea (including ossification of the cochlea)
-
The psychological status of the individual is unstable
-
The individual has unrealistic expectations
-
Acute cholesteatoma
-
History of vestibular schwannoma
-
Unstable Meniere's disease
-
Auditory Neuropathy
-
Epilepsy not responding to treatment
-
Permanent inability and/or unwillingness to participation in post-operative care and rehabilitation
-
Known intellectual disability and/or psychological diseases
-
Participation in other pharmacological clinical trials within four weeks prior to enrolment
-
Anything that, in the opinion of the Investigator, would
- place the subject at increased risk
- preclude the subject's full compliance with or completion of the study
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: TICI recipients
Participants in this clinical investigation will be implanted with an Mi2000 TICI totally cochlear implant |
Participants in this clinical investigation will receive a totally implantable cochlear implant. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Word Test in Quiet
Tidsramme: Pre-op to 6 months after first fitting
|
Word recognition in quiet, on a scale from 0 to 100% correct, higher scores indicate better outcomes |
Pre-op to 6 months after first fitting
|
|
Sentence Test in Noise
Tidsramme: Pre-op to 6 months after first fitting
|
Oldenburg Matrix Test, results measured in dB signal-to-noise ratio (SNR) with a range of +30 to -10 dB SNR, lower values indicating better outcomes |
Pre-op to 6 months after first fitting
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Health Utility Index Mark 3 (HUI3)
Tidsramme: Pre-op to 6 months after first fitting
|
Health utility scale: 1.00: Perfect health. 0.00: Death. Negative values: States worse than death. |
Pre-op to 6 months after first fitting
|
|
Nijmegen Cochlear Implant Questionnaire (NCIQ)
Tidsramme: Pre-op to 6 months after first fitting
|
Disease specific Quality of Life, overall score is on a scale from 0 to 100, higher numbers indicating better outcomes |
Pre-op to 6 months after first fitting
|
|
Change in body sound perception
Tidsramme: through study completion, an average of 12 months after first fitting
|
Participant reported scale on body sound perception (0 - no disturbance to 10 - very disturbing) |
through study completion, an average of 12 months after first fitting
|
|
Change in stigma perception
Tidsramme: through study completion, an average of 12 months after first fitting
|
Participant reported scale on stigma perception (0 - no stigmatization to 10 - strong stigmatization) |
through study completion, an average of 12 months after first fitting
|
|
Change in comfort perception
Tidsramme: through study completion, an average of 12 months after first fitting
|
Participant reported scale on stigma perception (0 - not comfortable to 10 - very comfortable) |
through study completion, an average of 12 months after first fitting
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Word test in quiet
Tidsramme: through study completion, an average of 12 months after first fitting
|
Word recognition in quiet, on a scale from 0 to 100% correct, higher scores indicate better outcomes |
through study completion, an average of 12 months after first fitting
|
|
Sentence Test in Noise
Tidsramme: through study completion, an average of 12 months after first fitting
|
Oldenburg Matrix Test, results measured in dB signal-to-noise ratio (SNR) with a range of +30 to -10 dB SNR, lower values indicating better outcomes |
through study completion, an average of 12 months after first fitting
|
|
Health Utility Index Mark 3 (HUI3)
Tidsramme: through study completion, an average of 12 months after first fitting
|
Health utility scale: 1.00: Perfect health. 0.00: Death. Negative values: States worse than death. |
through study completion, an average of 12 months after first fitting
|
|
Nijmegen Cochlear Implant Questionnaire (NCIQ)
Tidsramme: through study completion, an average of 12 months after first fitting
|
Disease specific Quality of Life, overall score is on a scale from 0 to 100, higher numbers indicating better outcomes |
through study completion, an average of 12 months after first fitting
|
|
Speech, Spatial, Quality of Hearing (SSQ12)
Tidsramme: through study completion, an average of 12 months after first fitting
|
Speech, Spatial and Quality of hearing scale from 0 to 10, higher numbers indicating better outcomes |
through study completion, an average of 12 months after first fitting
|
|
Hearing Implant Sound Quality Index (HISQUI)
Tidsramme: through study completion, an average of 12 months after first fitting
|
Sound quality score ranging from 19 (very poor sound quality) to 133 (very good sound quality) |
through study completion, an average of 12 months after first fitting
|
|
Tinnitus Functional Index (TFI)
Tidsramme: through study completion, an average of 12 months after first fitting
|
Tinnitus questionnaire measures the severity and negative impact of tinnitus on a 0 (Not a Problem / Slight Tinnitus) to 100 (Very Big Problem / Very Severe Tinnitus) scale |
through study completion, an average of 12 months after first fitting
|
|
Audiogram
Tidsramme: through study completion, an average of 12 months after first fitting
|
Pure-tone air-conduction hearing thresholds will be measured in each ear. The threshold is the lowest sound level, in decibels hearing level (dB HL), at which the participant responds. The outcome is the threshold at each frequency. Higher thresholds mean poorer hearing; lower thresholds better hearing. |
through study completion, an average of 12 months after first fitting
|
Samarbeidspartnere og etterforskere
Etterforskere
- Studieleder: Florian Schwarze, MED-EL
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Nevrologiske manifestasjoner
- Sykdommer i nervesystemet
- Otorhinolaryngologiske sykdommer
- Sensasjonsforstyrrelser
- Øresykdommer
- Hørselsforstyrrelser
- Patologiske tilstander, tegn og symptomer
- Tegn og symptomer
- Hørselstap
- Kirurgiske prosedyrer, operativ
- Proteseimplantasjon
- Otorhinolaryngologiske kirurgiske inngrep
- Otologiske kirurgiske inngrep
- Cochleaimplantasjon
Andre studie-ID-numre
- MED-EL_CRD_2026_03
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .